We are advancing a deep pipeline of candidates for validated targets and evaluating expansion to emerging targets, each in areas of high unmet medical need.

Zenas innovation is defined by the selection of product candidates that are designed with best-in-class potential and then advanced utilizing differentiated development and commercial strategies to address patient needs AND the value requirements of the dynamic healthcare environment. Zenas innovation further includes acquiring or discovering first-in-class product candidates based upon new knowledge in the evolving field of immunology.

Our lead candidate, ZB001, is an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb) that we are developing for the potential treatment of patients in China with thyroid eye disease (TED). TED is a debilitating condition that significantly impacts quality of life and can cause proptosis (“bulging eyes”), double vision and vision loss. Zenas exclusively licensed China rights to develop and commercialize ZB001 from Viridian Therapeutics, Inc. ZB001 has first-in-class potential in China and the program is advancing rapidly with an expected Investigational New Drug application filing by Viridian in late 2021, followed by a Zenas filing in China.

Research
Preclinical
Clinical
Territory
Partner
ZB001
(anti-IGF1R mAb for Thyroid Eye Disease)
2022
Territory:
China
ZB011
(anti-IGF1R mAb for Thyroid Eye Disease)
2022
Territory:
China
ZB002
(autoimmune)
2022
Territory:
Worldwide
ZB003
(autoimmune)
2022
Territory:
Worldwide
ZB004
(autoimmune)
2022
Territory:
Worldwide
ZB005
(autoimmune)
2022
Territory:
China
ZB006
(autoimmune)
2023
Territory:
China
long-arrow-right-regularfacebook-brandsfacebook-f-brandsinstagram-brandslinkedin-brandslinkedin-in-brandssubmit-arrowtwitter-brandstwitter-square-brandsyoutube-brands